FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds
Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.
You may also be interested in...
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.
Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.